Safety and efficacy of arabinoxylan Rice Bran (MGN-3) in combination with interventional therapies in the treatment of liver cancer.

Trial Profile

Safety and efficacy of arabinoxylan Rice Bran (MGN-3) in combination with interventional therapies in the treatment of liver cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2011

At a glance

  • Drugs MGN 3 (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top